Category Archives: Strategy

Risking It All? Risk-Based Monitoring at Cancer Research UK

“Only those who risk going too far can possibly find out how far they can go,” said T.S. Elliot. Cancer Research UK (CRUK) followed this advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials. This decision has revealed how risk-adjusted approaches […]
Also posted in R&D | Tagged , , , , | Leave a comment

‘Warehousing’ and the Future of HCV Treatment

The battle against hepatitis C (HCV) is a relatively new, and highly dynamic, one.  The viral disease was only discovered in the 1980’s and, according to WHO estimates, some 3% of the world’s population are now infected with HCV and there are more than 170 million chronic carriers. So what does the HCV treatment landscape look […]
Also posted in healthcare | Tagged , , | Leave a comment

Tufts Figures on Drug Development Spark Debate

By Agnes Shanley, Pharmaceutical Technology. The Tufts University Center for the Study of Drug Development (CSDD) released its latest research on the costs and timeframes required for launching a new drug. Although the study acknowledges that it still takes about 10 years to launch a new brand-name pharmaceutical, this year, the costs required were estimated at $2.6 […]
Also posted in R&D | Tagged , , | 1 Comment

Shire to Relocate More Than 500 Jobs to Lexington, MA

Shire plans to relocate more than 500 positions to Massachusetts from its Chesterbrook, PA, site and establish Lexington, MA, as the company’s US operational headquarters. The transition is a continuation of the company’s “One Shire” efficiency program and will streamline business globally through two principal locations—Massachusetts and Switzerland—with support from a limited number of regional […]
Posted in Strategy | Tagged , | Leave a comment

GSK and Novo Nordisk Lead on Access Index

Last week, the Access to Medicine Foundation released its 2014 Index rating the performance of companies in broadening access to medicines in low and middle-income countries. For the fourth time, GSK leads the index with Novo Nordisk taking second. J&J. Novartis, Gilead and Merck KGaA rank three to six with nearly even scores.
Posted in Strategy | Leave a comment
  • Categories

  • Meta